期刊
CHEMISTRY & BIOLOGY
卷 16, 期 2, 页码 112-120出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2009.01.004
关键词
-
资金
- Institut National de la Sante et de la Recherche Medicale
- Commissariat a l'energie Atomique
- Ligue Nationale contre le Cancer
- Institut National contre le Cancer
- Agence Nationale de la Recherche [ANR-08-PCVI-0005-02]
- Agence Nationale de la Recherche (ANR) [ANR-08-PCVI-0005] Funding Source: Agence Nationale de la Recherche (ANR)
Protein kinases are central components of signal transduction cascades often dysregulated in cancer, and they represent some of the most promising drug targets. However, the target selectivity is a major concern because most described kinase inhibitors target the highly conserved ATP-binding pocket. Recently, new classes of inhibitors that do not compete with ATP and exhibit different mechanisms of action have been described. Overexpression of protein kinase CK2 is an unfavorable prognostic marker in several cancers. Consequently, CK2 has emerged as a relevant therapeutic target. Several classes of ATP-competitive inhibitors have been identified, showing variable effectiveness. The molecular architecture of this multisubunit enzyme could offer alternative strategies to inhibit CK2 functions, and this review illustrates these emerging possibilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据